Format

Send to

Choose Destination
See comment in PubMed Commons below
Expert Opin Drug Deliv. 2006 Nov;3(6):707-12.

The CNS as a target for peptides and peptide-based drugs.

Author information

1
Veterans Affairs Medical Center - St. Louis and Saint Louis University School of Medicine, Geriatric Research, Education and Clinical Center, Division of Geriatrics, Department of Internal Medicine, St. Louis, MO 63106, USA. bankswa@slu.edu

Abstract

Peptides hold great potential as CNS drugs, but their delivery to the CNS is problematic. However, actual roadblocks to peptide delivery are different from those often perceived. Many peptides cross the blood-brain barrier by saturable and non-saturable mechanisms, and accumulate in brain in amounts sufficient to produce physiological effects. Peripheral factors (e.g., short half-life in blood) can be dominant factors limiting therapeutic use. Production of therapeutics that are enzymatically resistant and have long circulation times, even when the blood-brain barrier penetration is low, can result in substances with significant CNS accumulation. Surprisingly low amounts of peptide in brain can result in CNS effects, and so the dose needed for brain delivery is generally much smaller than for peripheral tissues. Brain-to-blood transporters can greatly limit CNS accumulation of a potential therapeutic. Finally, intranasal and intrathecal routes may be especially useful for substances that are rapidly degraded in blood or are large and hydrophobic, respectively.

PMID:
17076593
DOI:
10.1517/17425247.3.6.707
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis
    Loading ...
    Support Center